Oragenics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. (d/b/a ONI BioPharma Inc.) on December 10, 2008. The report details a significant corporate event regarding the company's admission to a new stock exchange.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate listing event rather than financial performance data.
Material Changes
On December 10, 2008, the Alternext Paris admission committee approved the Company's listing application. Key details include:
- Listing Status: Admitted to the Alternext Paris exchange.
- Trading Symbol: ALONI.
- Commencement Date: Trading began on December 15, 2008.
- Significance: ONI BioPharma is the first United States-based company to be listed on the Alternext Paris exchange.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or specific risk factors related to operations. The report notes that information referenced in the accompanying press release (Exhibit 99.1) regarding the company website is not intended to be part of this Form 8-K.
Investor Verification Checklist
- Verify the commencement of trading under the symbol "ALONI" on the Alternext Paris exchange on December 15, 2008.
- Review the press release furnished as Exhibit 99.1 for additional context on the listing.
- Confirm the company's status as the first U.S.-based entity on this specific exchange.